What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
Keith T. Flaherty mainly investigates Melanoma, Internal medicine, Cancer research, Oncology and Surgery.
His Melanoma research incorporates themes from Cancer, Trametinib and Immunology.
In his study, Survival rate and Nausea is strongly linked to Gastroenterology, which falls under the umbrella field of Internal medicine.
He has included themes like Immune checkpoint, Immunotherapy and Kinase, MAPK/ERK pathway in his Cancer research study.
The study incorporates disciplines such as Clinical trial, Disease, Retrospective cohort study and Cohort in addition to Oncology.
His studies in Surgery integrate themes in fields like Binimetinib, Placebo and Sorafenib.
His most cited work include:
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation (5698 citations)
- Final Version of 2009 AJCC Melanoma Staging and Classification (3479 citations)
- Inhibition of mutated, activated BRAF in metastatic melanoma. (2901 citations)
What are the main themes of his work throughout his whole career to date?
Keith T. Flaherty spends much of his time researching Melanoma, Internal medicine, Cancer research, Oncology and Cancer.
His study of Vemurafenib is a part of Melanoma.
His studies deal with areas such as V600E and Ipilimumab as well as Vemurafenib.
Keith T. Flaherty interconnects Surgery and Trametinib in the investigation of issues within Internal medicine.
His Cancer research research focuses on subjects like MAPK/ERK pathway, which are linked to Protein kinase A.
His Oncology research is multidisciplinary, incorporating perspectives in Phases of clinical research, Sorafenib, Adverse effect, Pharmacology and Dacarbazine.
He most often published in these fields:
- Melanoma (55.80%)
- Internal medicine (42.32%)
- Cancer research (40.70%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (42.32%)
- Melanoma (55.80%)
- Oncology (35.85%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Internal medicine, Melanoma, Oncology, Cancer research and In patient.
His research in Internal medicine intersects with topics in Gastroenterology and MEDLINE.
His study in Melanoma is interdisciplinary in nature, drawing from both Immune checkpoint, Advanced melanoma, Blockade, Immune system and Immunotherapy.
His Oncology research is multidisciplinary, relying on both Clinical trial, Vemurafenib, Dabrafenib, MEK inhibitor and Trametinib.
Specifically, his work in Vemurafenib is concerned with the study of Cobimetinib.
His Cancer research research integrates issues from Cell, T cell, Downregulation and upregulation, Targeted therapy and MAPK/ERK pathway.
Between 2018 and 2021, his most popular works were:
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. (278 citations)
- Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (109 citations)
- SARS-CoV-2 viral load is associated with increased disease severity and mortality. (95 citations)
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
